The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Open accessAbstract
CD38, an adenine dinucleotide phosphate (ADP) ribose cyclase and a cyclic ADP ribose hydrolase, is widely expressed on the surface of multiple myeloma (MM) cells. It is known to play a pivotal role in the downstream pathways that mediate MM cell growth, signal transduction, and adhesion. The clinical use of CD38 monoclonal antibodies (MoAbs), such as daratumumab, either as monotherapy or in combination with other anti-MM agents, has produced impressive results in patients who have failed standard MM therapy. CD38 MoAbs exhibit several cytotoxic mechanisms on MM cells. In addition to the classical effector mechanisms associated with antibody therapy, CD38 MoAbs induce MM apoptosis and clonal T-cell expansion. Here, we summarize the results of some pivotal clinical studies using a human CD38 MoAb, daratumumab, in patients with MM, discuss the anti-MM effector mechanisms induced by CD38 MoAbs, and review the potential tumor antigens that may be suitable targets for immunotherapy of MM. Finally, we present a paradigm of immunotherapy for MM patients using CD38 MoAbs followed by GM-CSF and an immune checkpoint inhibitor in patients who have undergone high dose chemotherapy and autologous stem cell transplant. CD38 MoAbs have emerged as a novel and ultimately very promising immunotherapeutic agent for MM because of its ability to induce MM cytotoxicity through both arms of the adaptive immune responses.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD38 inhibition in humans has recently been targeted using biologicals such as CD38-specific blocking antibodies.
“CD38 inhibition in humans has been recently targeted using biologicals such as CD38-specific blocking antibodies (Shallis et al., 2017).”
From A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline (2018) · cites this paper as Shallis et al., 2017
Several CD38-specific antibodies are being studied or have been approved by the FDA for treating human cancers.
“several of these antibodies are either being studied or have been approved by the FDA for the treatment of human cancers (Shallis et al., 2017).”
From A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline (2018) · cites this paper as Shallis et al., 2017
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129 · see citing works
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · see citing works
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037 · see citing works
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001 · see citing works
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B. M. P., Bald, J., Plesner, T., Syed, K. W., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 961 · see citing works
Caux, C., Vanbervliet, B., Massacrier, C., Dezutter‐Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., & Banchereau, J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.2.695 · Cited by 920 · see citing works
Davies, F. E., Raje, N. S., Hideshima, T., Lentzsch, S., Young, G. Q., Tai, Y., Lin, B. K., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 912 · see citing works
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778 · see citing works
Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by Lymphocyte Antigen CD38
Howard, M., Grimaldi, J. C., Bazán, J. F., Lund, F. E., Santos‐Argumedo, L., Parkhouse, R. M. E., Walseth, T. F., & Lee, H. C. (1993) · Science · doi:10.1126/science.8235624 · Cited by 737 · see citing works
Liu, J., Hamrouni, A., Wołowiec, D., Coiteux, V., Kuliczkowski, K., Hétuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580 · see citing works
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · see citing works
Identification of proliferating dendritic cell precursors in mouse blood.
Inaba, K., Steinman, R. M., Pack, M., et al. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.5.1157 · Cited by 451 · see citing works
Partida-Sánchez, S., Cockayne, D. A., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K., Goodrich, S., Howard, M., Harmsen, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1209 · Cited by 450 · see citing works
Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353 · see citing works
Human CD38: a glycoprotein in search of a function
Malavasi, F., Funaro, A., Roggero, S., Horenstein, A. L., Calosso, L., & Mehta, K. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90148-1 · Cited by 344 · see citing works
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333 · see citing works
Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N. S., Kumar, S. K., Chauhan, D., Treon, S. P., Richardson, P. G. G., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323 · see citing works
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 322 · see citing works
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle‐Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 322 · see citing works
Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose
Guse, A. H., da Silva, C. P., Berg, I., Skapenko, A., Weber, K., Heyer, P., HOHENEGGER, M., Ashamu, G. A., Schulze‐Koops, H., Potter, B. V. L., et al. (1999) · Nature · doi:10.1038/18024 · Cited by 309 · see citing works
Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M. L., Yang, J., & Yi, Q. (2009) · Blood · doi:10.1182/blood-2009-05-220285 · Cited by 309 · see citing works
Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297 · see citing works
Lokhorst, H. M., Schattenberg, A. V. M. B., Cornelissen, J. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3031 · Cited by 287 · see citing works
Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M. G., Palumbo, G. A., Introna, M., & Golay, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713732 · Cited by 270 · see citing works
Hasegawa, Y., Takanashi, S., Kanehira, Y., Tsushima, T., Imai, T., & Okumura, K. (2001) · Cancer · doi:10.1002/1097-0142(20010301)91:5 · Cited by 240 · see citing works
Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., Hyodo, H., Shinya, E., Takahashi, H., Dong, H., et al. (2012) · Leukemia · doi:10.1038/leu.2012.213 · Cited by 226 · see citing works
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T. (2010) · Haematologica · doi:10.3324/haematol.2010.030759 · Cited by 217 · see citing works
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia · doi:10.1038/leu.2015.79 · Cited by 192 · see citing works
Jungbluth, A. A., Ely, S. A., DiLiberto, M., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4931 · Cited by 182 · see citing works
Ahlers, J., Dunlop, N. M., Alling, D. W., Nara, P. L., & Berzofsky, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3947 · Cited by 154 · see citing works
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
Hallett, W. H. D., Jing, W., Drobyski, W. R., & Johnson, B. D. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2011.03.011 · Cited by 152 · see citing works
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151 · see citing works
Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma
Lim, S. H., Wang, Z., Chiriva‐Internati, M., et al. (2001) · Blood · doi:10.1182/blood.v97.5.1508 · Cited by 133 · see citing works
Self-citationWen, Y. J., Ling, M., Bailey-Wood, R., et al. (1998) · PubMed · Cited by 130 · see citing works
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, T., Arkenau, H., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A. P., Lisby, S., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726729 · Cited by 109 · see citing works
Gasser, A. S., Bruhn, S., & Guse, A. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601347200 · Cited by 105 · see citing works
Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment
Qu, P., Wang, L., & Lin, P. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.022 · Cited by 103 · see citing works
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Chiriva‐Internati, M., Wang, Z., Salati, E., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0408 · Cited by 101 · see citing works
Kearl, T. J., Jing, W., Gershan, J. A., & Johnson, B. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202005 · Cited by 92 · see citing works
Suen, H., Brown, R. D., Yang, S. S., Ho, P. J., Gibson, J., & Joshua, D. E. (2015) · Leukemia · doi:10.1038/leu.2015.104 · Cited by 91 · see citing works
Yousef, S., Marvin, J., Steinbach, M. N., Langemo, A., Kovacsovics, T. J., Binder, M., Kröger, N. M., Luetkens, T., & Atanackovic, D. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.7 · Cited by 90 · see citing works
Nair, J. R., Carlson, L. M., Koorella, C., Rozanski, C. H., Byrne, G. E., Bergsagel, P. L., Shaughnessy, J. P., Boise, L., Chanan-Khan, A. A., & Lee, K. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100016 · Cited by 89 · see citing works
Muñoz, P., Mittelbrunn, M., de la Fuente, H., Pérez‐Martínez, M., García-Pérez, A., Ariza, A., Malavasi, F., Zubiaur, M., Sánchez‐Madrid, F., & Sancho, J. (2008) · Blood · doi:10.1182/blood-2007-07-101600 · Cited by 82 · see citing works
Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma
Batchu, R. B., Moreno, A., Szmania, S. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1383 · Cited by 65 · see citing works
Brown, R. D., Spencer, A. G., Ho, P. J., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., & Joshua, D. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903216804 · Cited by 49 · see citing works
The Spermatozoa Protein, SLLP1, Is a Novel Cancer–Testis Antigen in Hematologic Malignancies
Wang, Z., Zhang, Y., Mandal, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0911 · Cited by 41 · see citing works
Immunogenicity and cross‐reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma
Wen, Y., Ling, M., & Lim, S. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00592.x · Cited by 32 · see citing works
Self-citationWang, Z., Zhang, J., Zhang, Y., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21499 · Cited by 31 · see citing works
Pattern of Gene Expression and Immune Responses to Semenogelin 1 in Chronic Hematologic Malignancies
Zhang, Y., Wang, Z., Liu, H., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200311000-00001 · Cited by 29 · see citing works
Li, Z., Li, W., Meklat, F., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22842 · Cited by 24 · see citing works
Sp17 gene expression in myeloma cells is regulated by promoter methylation
Wang, Z., Zhang, Y., Ramsahoye, B. H., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602160 · Cited by 24 · see citing works
Smans, K. A., Ingvarsson, M. B., Lindgren, P., Canevari, S., Walt, H., Stigbrand, T. I., m, T. R. B. C., & Mill�n, J. L. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991008)83:2 · Cited by 14 · see citing works
Semenogelin I expression in myeloma cells can be upregulated pharmacologically
Zhang, Y., Wang, Z., Zhang, J., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.03.036 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tarragó, M. G., Chini, C. C. S., Kanamori, K. S., Warner, G. M., Caride, A., de Oliveira, G. C., Rud, M., Samani, A., Hein, K. Z., Huang, R., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.016 · Cited by 384 · see citing works
- Authors
- Shallis, R. M., Terry, C. M., & Lim, S. H.
- Affiliations
- Brown University (US)
- Corresponding author
- Lim, Seah H.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2017-03-24
- Volume
- 66
- Issue
- 6
- Pages
- 697-703
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029060
- OpenAlex
- W2604037073
- Cited by
- 20
- References
- 57
- Citations by year
- 2025: 3 · 2024: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 9
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- CD38, multiple myeloma, daratumumab, monoclonal antibodies, ADP-ribosyl cyclase, cyclic ADP-ribose, apoptosis, T cell expansion, effector mechanisms, tumor antigens, immunotherapy, immune checkpoint inhibitors, GM-CSF, autologous stem cell transplantation, relapsed/refractory multiple myeloma
- MeSH terms
- Antibodies, Monoclonal, Humans, Immunotherapy, Multiple Myeloma, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
